Bioactive suture: A novel immunotherapy for head and neck cancer

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 7088-7099

  Shibuya, Terry Y ^a,b   Kim, Sanghun ^a   Nguyen, Kevin ^a   Do, Johnny ^c   McLaren, Christine E ^a,b   Li, Kuo Tung ^b   Chen, Wen Pin ^a   Parikh, Parag ^a   Wadhwa, Ashish ^a   Zi, Xiaolin ^a,b   Chen, Vincent Y ^a   Wong, Hau Sin ^a   Armstrong, William B ^a,b   Yoo, George H ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CD40 LIGAND; CELL NUCLEUS DNA; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA BINDING; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; HEAD CANCER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MATERIAL COATING; NECK CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; SUTURE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ADULT; AGED; AGED, 80 AND OVER; BIOCOMPATIBLE MATERIALS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PHENOTYPE; SUTURE TECHNIQUES; T-LYMPHOCYTES;

EID: 6044236871     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0052     Document Type: Article

References (40)

1. Myers JN, Whiteside TL. Immunotherapy of squamous cell carcinoma of the head and neck. In: Myers E, Suen J, editors. Cancer of the head and neck, 3rd ed. Philadelphia: W.B. Saunders Comp; 1995. p. 805-17.
2. Hadden JW. The immunopharmacology of head and neck cancer: an update. Int J Immunopharmacol 1997;19:629-44.
3. Shibuya TY, Lum LG, Pawlowski T, Whiteside TL. Immunology and immunotherapy for head and neck cancer. In: Ensley JF, Gutkind SJ, Jacobs JR, Lippman SM, editors. Head and neck cancers. San Diego: Academic Press; 2003. p. 569-91.
4. Valone FH, Gandara DR, Diesseroth AB, et al. Interleukin-2, cisplatinum, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J Immunother 1991;10:207-13.
5. Mantovani G, Bianchi A, Curreli L. et al. Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL2 in advanced squamous cell carcinoma of the head and neck: a pilot study. Biotherapy 1994;8:91-8.
6. Airoldi M, De Stefani A, Marchionatti S, et al. Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy. Head Neck 2001;23:298-304.
7. Tamura T, Sasaki Y, Shinkai T, et al. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy. Cancer Res 1989;49:730-5.
8. Schantz SP, Dimery I, Lippman SM, Clayman GL, Pellegrino C, Morice R. A phase II study of interleukin-2 and interferon-alpha in head and neck cancer. Investig New Drugs 1992;10:217-23.
9. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
10. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
11. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-85.
12. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-80.
13. Cortesina G, De Stefani A, Galeazzi E, et al. The effect of preoperative local interleukin-2 (IL-2) injections in patients with head and neck squamous cell carcinoma. An immunologic study. Acta Otolaryngol 1991;111:428-33.
14. Squadrelli-Saraceno M, Rivoltini L, Cantu G, Ravagnani F, Parmiani G, Molinari R. Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2. Tumori 1990; 76:566-71.
15. Mattijssen V, De Mulder PH, Schornagel JH, et al. Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma. J Immunother 1991;10:63-8.
16. Cortesina G, De Stefani A, Majore L, Forni G, Galeazzi E. Locoregional treatment with low and high doses of interleukin-2 of head and neck squamous cell carcinoma recurrences. Acta Otorhinolaryngol Ital 1994;14:3-9.
17. Shibuya TY, Wei WZ, Zormeier M, et al. Anti-CD3/anti-CD28 MoAb coated suture enhances HNSCC patients immune response. Arch Otolaryngol Head Neck Surg 1999;25:1229-34.
18. Shibuya TY, Kim S, Nguyen K, et al. Covalent linking of proteins and cytokines to suture: enhancing the immune response of head & neck cancer patients. Laryngoscope 2003;113:1870-84.
19. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
20. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-66.
21. Shibuya TY, Wei WZ, Zormeier M, et al. Anti-CD3/anti-CD28 bead overcomes suppressed T cell responses in HNSCC patients. Arch Otolaryngol Head Neck Surg 2000;26:473-9.
22. Ferlazzo G, Wesa A, Wei WZ, Galy A. Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells. J Immunol 1999;163:3597-604.
23. Harant H, De Martin R, Andrew PJ, Folgalr E, Dittrich C, Lindley IJ. Synergistic activation of interleukin-8 gene transcription by all-transretinoic acid and tumor necrosis factor-alpha involves the transcription factor NF-kappaB. J Biol Chem 1996;271:26954-61.
24. Brunner E, Domhof S, Langer F. Nonparametric analysis of longitudinal data in factorial experiments. New York: J. Wiley Publishers; 2002. p. 219-224.
25. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000;289:1560-3.
26. Schubert LA, Cron RQ, Cleary AM, et al. A T cell-specific enhancer of the human CD40 ligand gene. J Bio Chem 2002;277:7386-95.
27. Srahna M, Remacle JE, Annamalai K, et al. NF-κB is involved in the regulation of CD154 (CD40 ligand) expression in primary T cells. Clin Exp Immunol 2001;125:229-36.
28. Parra E, Mustelin T, Dohlsten M, Mercola D. Identification of a CD28 response element in the CD40 ligand promoter. J Immuno 2001; 166:2437-43.
29. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002;8:3137-45.
30. Hoffman TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck and its clinical importance. Clin Cancer Res 2002;8:2553-62.
31. Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT, Whiteside TL. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 1999;5: 1263-73.
32. Shibuya TY, Nugyen N, McLaren CE, et al. Clinical significance of poor CD3 response in head and neck cancer. Clin Cancer Res 2002;8: 745-51.
33. Levine BL, Mosca JD, Riley JL, et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science (Wash DC) 1996;272:1939-43.
34. Levine BL, Cotte J, Small CC, et al. Large-scale production of CD4+ T cells from HIV-1 infected donors after CD3/CD28 costimulation. J Hematother 1998;7:437-48.
35. Levine BL, Bernstein WB, Connors M, et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997;159:5921-30.
36. Levine BL, Bernstein WB, Aronson NE, et al. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002;8:47-53.
37. Walker RE, Bechtel CM, Natarajan V, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000;96:467-74.
38. Lum LG, LeFever AV, Treisman JS, Garlie NK, Hanson JP Jr. Immune modulation in cancer patients with adoptive transfer of anti-CD3/anti-CD28 costimulated T cells-phase I clinical trial. J Immunother 2001;24:408-19.
39. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial-presenting cells. Nat Med 2003;9: 619-25.
40. Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL. A cell-based artificial antigen-presenting cell coated with anti-CD3 and anti-CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol 2002;105:259-72.